Analysis
Lantheus Holdings agreed to be acquired by Curium US Holdings in an all-cash deal that could be worth up to $8.0 billion, the companies announced August 3. Curium will pay $102.50 per share in cash at closing, plus non-transferable contingent value rights worth up to $12.00 per share tied to commercial milestones through 2030 -- a total potential consideration of up to $114.50 per share, according to GlobeNewswire and Hospital Management.
The combination would create a radiopharmaceutical company spanning both diagnostics and therapeutics, with infrastructure the companies say can serve patients in more than 70 countries. Lantheus's board has unanimously approved the deal, which still needs regulatory clearance and Lantheus shareholder approval before an expected close in the first half of 2027.
“That structure has shown up in a handful of biopharma deals this cycle and is becoming a standard way to bridge a valuation gap between buyer caution and seller ambition.”
The CVR structure is the notable detail for anyone tracking how public-company M&A is getting priced this cycle: rather than a flat cash number, roughly 10% of the maximum deal value is contingent on Lantheus hitting specific commercial milestones over the next four years -- a hedge that lets the acquirer avoid overpaying for pipeline assets that haven't yet proven out, while giving Lantheus shareholders upside if they do. That structure has shown up in a handful of biopharma deals this cycle and is becoming a standard way to bridge a valuation gap between buyer caution and seller ambition.
